Mesaros Oana, Veres Stefana, Onciul Madalina, Matei Emilia, Jimbu Laura, Neaga Alexandra, Zdrenghea Mihnea
Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, ROU.
Hematology, Ion Chiricuta Oncology Institute, Cluj-Napoca, ROU.
Cureus. 2024 Sep 6;16(9):e68770. doi: 10.7759/cureus.68770. eCollection 2024 Sep.
MiRNAs are a class of non-coding RNAs acting as gene expression regulators by modulating the lifespan of messenger RNA. Commonly referred to as the most frequent leukemia in the Western world, chronic lymphocytic leukemia (CLL) is a lymphoproliferative malignancy characterized by clonal expansion of CD19, CD23, and CD5-positive mature B-cells. While this pathology is regarded as less aggressive and has a variety of treatment options, the cause of its clinical heterogeneity is not yet understood. Moreover, the prognostic markers and treatment recommendations based on predictive markers are limited. This review aims to investigate some miRNAs that are dysregulated and possibly involved in CLL pathogenesis as a starting point for the proposal of new prognostic and predictive markers and, as more agents targeting miRNA expression become available, their potential role as therapeutic targets.
微小RNA(miRNAs)是一类非编码RNA,通过调节信使RNA的寿命来充当基因表达调节剂。慢性淋巴细胞白血病(CLL)通常被称为西方世界最常见的白血病,是一种淋巴细胞增殖性恶性肿瘤,其特征是CD19、CD23和CD5阳性成熟B细胞的克隆性扩增。虽然这种病理被认为侵袭性较小且有多种治疗选择,但其临床异质性的原因尚未明确。此外,基于预测性标志物的预后标志物和治疗建议也很有限。本综述旨在研究一些失调且可能参与CLL发病机制的微小RNA,以此作为提出新的预后和预测性标志物的起点,并且随着更多靶向微小RNA表达的药物问世,探讨它们作为治疗靶点的潜在作用。